Introduction: Immune checkpoint inhibitors (ICI) are becoming a cornerstone of therapies for many cancers. However, a new class of side effects has emerged, namely immune-related adverse events (irAEs). Many studies have suggested a potential relationship between irAEs and benefit of ICI, but little is known about the mechanisms underlying toxicity and antitumor efficacy.